Last reviewed · How we verify
MMR GlaxoSmithKline
MMR GlaxoSmithKline is a Live attenuated viral vaccine Biologic drug developed by The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz). It is currently in Phase 3 development for Prevention of measles, mumps, and rubella in children and adults. Also known as: MMR Bio-Manguinhos.
MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.
GlaxoSmithKline developed the MMR vaccine, known as Priorix, which is a small molecule used to prevent Rubella, Mumps, and Measles. The vaccine has been studied in various clinical trials, including one assessing its safety and immunogenicity in healthy children aged 12 to 18 months in Singapore.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MMR GlaxoSmithKline |
|---|---|
| Also known as | MMR Bio-Manguinhos |
| Sponsor | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains live attenuated (weakened) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protective immunity against these three viral infections. The attenuated viruses are unable to cause the severe manifestations of wild-type infection while generating durable immunological memory.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, erythema, swelling)
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
Key clinical trials
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age (PHASE3)
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine (PHASE4)
- Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age (PHASE3)
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR GlaxoSmithKline CI brief — competitive landscape report
- MMR GlaxoSmithKline updates RSS · CI watch RSS
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) portfolio CI
Frequently asked questions about MMR GlaxoSmithKline
What is MMR GlaxoSmithKline?
How does MMR GlaxoSmithKline work?
What is MMR GlaxoSmithKline used for?
Who makes MMR GlaxoSmithKline?
Is MMR GlaxoSmithKline also known as anything else?
What drug class is MMR GlaxoSmithKline in?
What development phase is MMR GlaxoSmithKline in?
What are the side effects of MMR GlaxoSmithKline?
Related
- Drug class: All Live attenuated viral vaccine drugs
- Manufacturer: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of measles, mumps, and rubella in children and adults
- Also known as: MMR Bio-Manguinhos
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing